Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer

• Jamie D. Weyandt,

  Affiliation Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Benjamin L. Lampson,

  Current Address: Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

  Affiliation Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Sherry Tang,

  Affiliation Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Matthew Mastrodomenico,

  Affiliation Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Diana M. Cardona,

  Affiliation Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Christopher M. Counter

  * E-mail: count004@mc.duke.edu

  Affiliations Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America, Department of Radiation Oncology, Duke University Medical Center, Durham, NC, United States of America

  ⨯